National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

The MERIT Award

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

The Cancer Genome Atlas Reports Brain Tumors Study

NCI Research Coding and Reporting

NCI Launches Community Cancer Centers Pilot

The Nation's Investment in Cancer Research FY 2009

NCI Training and Career Development Inventory

New MERIT Award Winners Announced

caBIG: Connecting the Cancer Community

NCI Participation in the NIH Roadmap

Past Highlights
MERIT Award Recipient: I. George Miller, M.D.

I. George Miller   Sponsoring NCI Division:  Division of Cancer Biology (DCB)
Grant Number:R37CA12055
Award Approved:June 2003
Institution:Yale University
Department:Pediatrics
Scientific Abstract (CRISP)
I. George Miller at Yale University
Literature Search on PubMed

Studies of Epstein-Barr Virus

Dr. Miller's research focuses on the biology of Epstein-Barr virus (EBV), the first recognized human cancer virus. EBV is etiologically associated with several human cancers including nasopharyngeal cancer, gastric cancer, Hodgkin's lymphoma, Burkitt's lymphoma and immunoblastic lymphoma. The experiments proposed in Dr. Miller's MERIT award grant address seminal unanswered questions about the behavior of an important human cancer virus and address a basic unresolved question in virology, "How do viruses switch from a latent to a lytic life style?"

In previous work, Dr. Miller identified several key viral genes which regulate the virus life cycle, including one gene, termed ZEBRA (Z E B Replication Activator), which mediates a switch between latency, a state in which only a few viral genes are expressed, and the lytic cycle, a phase when mature viruses replicate. This switch between latency and lytic replication is essential for the virus to spread from one cell to another, and from one individual to another.

This essential component of the viral life cycle is a potential target for development of anti-viral strategies. The MERIT grant poses two central questions: "What controls the expression of the gene encoding ZEBRA?" and "How does ZEBRA protein activate the cascade leading to lytic cycle expression of the virus?" The answers to these questions should provide new approaches to prevent and treat EBV-associated cancers.

Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov